Skip to main content

Table 4 Dose modification in case of renal insufficiency

From: Amantadine for NeuroenhaNcement in acutE patients Study - a protocol for a prospective pilot proof of concept phase IIb study in intensive and intermediate care unit patients (ANNES)

Glomerular filtration rate (GFR) in ml/min

Dosage modification in mg

Administration interval

80 − 60

no dosage modification

 

60 − 50

no dosage modification

 

50 − 30

100 mg

1-1-0

No increase in non-responders

30 − 20

100 mg

1-0-0

no increase in non-responders

20 − 10

100 mg

1-0-0

no increase in non-responders

< 10 or hemodialysis

excluded from trial